The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RLMD | -41.21% | -93.58% | -42.26% | -96% |
| S&P | +14.5% | +93.32% | +14.09% | +241% |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Results from a human abuse potential study with REL-1017 exceeded expectations.
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $19.92M | -78.0% |
| Market Cap / Employee | $1.17M | 0.0% |
| Employees | 17 | -15.0% |
| Net Income | -$9.87M | 44.5% |
| EBITDA | -$10.22M | 45.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.35M | -35.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -147.18% | -57.3% |
| Return On Invested Capital | -113.88% | -27.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.40M | 51.7% |
| Operating Free Cash Flow | -$6.40M | 51.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.59 | 0.33 | 0.23 | 0.89 | -29.33% |
| Price to Tangible Book Value | 1.59 | 0.33 | 0.23 | 0.89 | -29.33% |
| Enterprise Value to EBITDA | -1.90 | 1.53 | 1.03 | 0.07 | -106.37% |
| Return on Equity | -116.6% | -132.3% | -160.3% | -175.1% | 74.42% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
